Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Qiagen (QGEN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Entrada Therapeutics Inc (TRDA – Research Report) and Qiagen (QGEN – Research Report).
Protect Your Portfolio Against Market Uncertainty
Entrada Therapeutics Inc (TRDA)
Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on Entrada Therapeutics Inc yesterday and set a price target of $21.00. The company's shares closed last Friday at $8.38.
According to TipRanks.com, Pachaiyappan is a 1-star analyst with an average return of -6.3% and a 34.3% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Gain Therapeutics, and Verona Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Entrada Therapeutics Inc with a $24.33 average price target, a 180.6% upside from current levels. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock.
Qiagen (QGEN)
In a report issued on May 8, Maja Pataki from Kepler Capital maintained a Hold rating on Qiagen, with a price target of EUR42.17. The company's shares closed last Friday at $41.86.
According to TipRanks.com, Pataki has 0 stars on 0-5 stars ranking scale with an average return of -13.7% and a 33.8% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Tecan Group AG, Demant, and Alcon.
Qiagen has an analyst consensus of Moderate Buy, with a price target consensus of $49.29, representing a 14.5% upside. In a report issued on April 24, UBS also maintained a Hold rating on the stock.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Breast Biopsy Devices Industry Outlook Report 2025-2030 with Case Study Analysis
Asia-Pacific is expected to witness significant expansion due to enhanced healthcare infrastructure and governmental initiatives. Industry leaders such as Hologic Inc., Danaher Corporation, and QIAGEN are prominent in the market landscape. Dublin, June 11, 2025 (GLOBE NEWSWIRE) -- The "Breast Biopsy Devices Market by Product, Procedure, Application, End User - Global Forecasts to 2030" has been added to offering. The global market for breast biopsy devices is anticipated to grow from USD 2.38 billion in 2025 to USD 3.26 billion by 2030, at a 6.5% CAGR. This growth is fueled by increasing breast cancer rates, the emphasis on early detection, and the preference for minimally invasive procedures, alongside effective state and provincial screening initiatives. The biopsy needles segment held the largest share of the market in 2024 The market comprises several segments, with biopsy needles accounting for a significant share. These are vital for diagnosing breast cancer through procedures like CNB, FNAB, and VAB, offering accurate results with minimal patient discomfort compared to surgical options. The needle breast biopsy procedure segment accounted for the largest market share in 2024 Needle breast biopsies are widely adopted due to their role in early and accurate diagnosis, supported by technological advancements in image guidance and needle design. Key growth factors include rising cancer rates, favorable reimbursement policies, and the preference for efficient outpatient care solutions. The liquid biopsy segment is projected to register the highest CAGR during the forecast period Liquid biopsies, which identify CTCs and ctDNA in the blood, offer a non-invasive alternative to traditional methods, aiding early diagnosis, treatment monitoring, and disease tracking. The segment's growth is driven by advances in molecular diagnostics and a trend towards personalized medicine, supported by regulatory policies and increased clinical awareness. The early cancer screening segment dominated the market in 2024 Early cancer screening is a pivotal application of biopsy technologies, offering the largest market share by facilitating detection at the earliest stage, thereby reducing mortality rates. Technological progress and an aging global population necessitate robust early monitoring solutions. Asia-Pacific is expected to register a significant growth rate in the market during the forecast period The Asia-Pacific region leads market growth due to increased breast cancer incidence, healthcare infrastructure enhancements, and heightened awareness. Investments in diagnostic technologies and favorable governmental and rural healthcare access improvements further encourage market expansion. The report provides insights into the following pointers: Analysis of growth modifiers, including technology advancements and regulatory influences impacting the breast biopsy market. In-depth product insights, R&D activities, and new launches within the breast biopsy sector. Diversification insights cover untapped geographies and innovative market products. Competitive analysis of notable market players' strategies and service offerings. Leading players include Hologic Inc., Danaher Corporation, Argon Medical Devices, Merit Medical Systems, Menarini-Silicon Biosystems, Varian Medical Systems, Inc., Planmed Oy, Sterylab S.R.L, Biocept, and Bio-Rad Laboratories. Key Attributes Report Attribute Details No. of Pages 290 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $2.38 Billion Forecasted Market Value (USD) by 2030 $3.26 Billion Compound Annual Growth Rate 6.5% Regions Covered Global Market Dynamics: Drivers: Growing Incidence of Breast Cancer Expansion of Private Diagnostic Chains and Imaging Centers Increasing Demand for Minimally Invasive and Non-Invasive Procedures Growing Awareness Regarding Early Detection of Breast Cancer Improved Reimbursement Scenario Challenges: Shortage of Skilled Professionals Opportunities: Technological Advancements Growing Collaboration and Financial Support from Public and Private Sectors Case Studies: Case Study 1: Pet-Guided Breast Biopsy Case Study 2: Early-Stage Breast Cancer Amid COVID Pandemic Case Study 3: Sampling Multiple Small Lesions in Dense Breast Tissue Companies Profiled in the Breast Biopsy Devices Market: Hologic, Inc. Danaher Corporation Becton, Dickinson and Company Argon Medical Qiagen Merit Medical Systems Menarini Silicon Biosystems S.p.A. Guardant Health, Inc. Neogenomics Laboratories, Inc. Sterylab S.R.L Biocept, Inc. Bio-Rad Laboratories, Inc. F. Hoffmann-La Roche Ltd. Exact Sciences Corporation Sysmex Inostics (A Subsidiary of Sysmex Corporation) Thermo Fisher Scientific Fujifilm Holdings Corporation Cardiff Oncology Inc. Myriad Genetics, Inc. Illumina, Inc. Fluxion Biosciences, Inc. INRAD, Inc. IZI Medical Products Remington Medical Inc. CP Medical For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
18 hours ago
- Business Insider
Analysts Offer Insights on Technology Companies: Nextdc Limited (OtherNXDCF) and Intuit (INTU)
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Nextdc Limited (NXDCF – Research Report) and Intuit (INTU – Research Report) with bullish sentiments. Confident Investing Starts Here: Nextdc Limited (NXDCF) In a report released today, Tim Plumbe from UBS maintained a Buy rating on Nextdc Limited, with a price target of A$20.20. The company's shares closed last Tuesday at $8.91, close to its 52-week low of $8.88. According to Plumbe is a 2-star analyst with an average return of 0.2% and a 41.7% success rate. Plumbe covers the NA sector, focusing on stocks such as Corporate Travel Management Limited, Flight Centre Travel Group Limited, and WEB Travel Group. Currently, the analyst consensus on Nextdc Limited is a Strong Buy with an average price target of $12.16, a 36.5% upside from current levels. In a report issued on May 27, Citi also maintained a Buy rating on the stock with a A$18.70 price target. Intuit (INTU) Jefferies analyst Brent Thill maintained a Buy rating on Intuit yesterday and set a price target of $850.00. The company's shares closed last Tuesday at $762.10. According to Thill is a 5-star analyst with an average return of 13.9% and a 65.7% success rate. Thill covers the Technology sector, focusing on stocks such as International Business Machines, CoreWeave, Inc. Class A, and Palantir Technologies. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intuit with a $814.71 average price target, representing a 6.9% upside. In a report issued on May 28, Scotiabank also maintained a Buy rating on the stock with a $800.00 price target.
Business Insider
a day ago
- Business Insider
Analysts Offer Insights on Industrial Goods Companies: Boeing (BA) and Symbotic (SYM)
Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Boeing (BA – Research Report) and Symbotic (SYM – Research Report). Confident Investing Starts Here: Boeing (BA) In a report released today, Gavin Parsons from UBS maintained a Buy rating on Boeing, with a price target of $245.00. The company's shares closed last Tuesday at $215.73. According to Parsons is a 4-star analyst with an average return of 6.6% and a 66.3% success rate. Parsons covers the Industrial Goods sector, focusing on stocks such as L3Harris Technologies, StandardAero, Inc., and Northrop Grumman. Boeing has an analyst consensus of Strong Buy, with a price target consensus of $219.95, a 1.1% upside from current levels. In a report issued on June 4, Jefferies also maintained a Buy rating on the stock with a $250.00 price target. Craig-Hallum analyst Greg Palm assigned a Hold rating to Symbotic today. The company's shares closed last Tuesday at $28.23. Symbotic has an analyst consensus of Moderate Buy, with a price target consensus of $29.63.
